Bladder symptoms in multiple sclerosis: A review of pathophysiology and management

Expert Opinion on Drug Safety

Volumn 9, Issue 6, 2010, Pages 905-915

  Nicholas, Richard ^a   Young, Carolyn ^b   Friede, Tim ^c  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Anticholinergics; Multiple sclerosis; Neurological disease; Overactive bladder syndrome; Urinary storage dysfunction; Urinary symptoms

Indexed keywords

BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; FLAVOATE CHLORIDE; MELADRAZINE TARTRATE; METHANTHELINE BROMIDE; MUSCARINIC RECEPTOR; OXYBUTYNIN; PROPANTHELLINE; TOLTERODINE; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; BLADDER TRAINING; BLURRED VISION; CHOLINERGIC SYSTEM; COCHRANE LIBRARY; COGNITIVE DEFECT; CONSTIPATION; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; INTERMITTENT CATHETERIZATION; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MICTURITION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROMODULATION; ONSET AGE; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PELVIC FLOOR MUSCLE TRAINING; PERIPHERAL NERVOUS SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; URINARY URGENCY; URODYNAMICS; UROLOGIC SURGERY;

CENTRAL NERVOUS SYSTEM DISEASES; CHOLINERGIC ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE; UROLOGIC DISEASES;

EID: 77958045445     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.501793     Document Type: Review

References (64)

1. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-394
2. Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003781
3. Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009;182:1442-1448
4. Athanasopoulos A, Perimenis P. Pharmacotherapy of urinary incontinence Int Urogynecol J Pelvic Floor Dysfunct 2009;20:475-482
5. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane database of systematic reviews 2009;1:CD004193
6. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178 (Pubitemid 34195211)
7. Fall M, Geirsson G, Lindstrom S. Discussion: functional classification of the overactive bladder. Urology 1997;50(Suppl 6A):34-35
8. Michel MC, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol 2009;56:298-308
9. Compston A, editor. McAlpine's multiple sclerosis, 4th edition. Churchill Livingstone, Oxford; 2005
10. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-146 (Pubitemid 19056478)
11. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399(6738 Suppl):A40-7
12. Koldewijn EL, Hommes OR, Lemmens WA, et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995;154:169-173
13. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999;246:1027-1032
14. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998;17:89-98
15. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999;161:743-757
16. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999;80:437-441
17. Gray R, Wagg A, Malone-Lee JG. Differences in detrusor contractile function in women with neuropathic and idiopathic detrusor instability. Br J Urol 1997;80:222-226
18. Gallien P, Robineau S, Nicolas B, et al. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil 1998;79:255-257
19. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology 2001;57:239-245
20. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol 2007;17:231-236
21. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-466
22. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-595 (Pubitemid 35333914)
23. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470-475
24. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
25. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
26. Hebjorn S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparingmethantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil). Urol Int 1977;32:209-217
27. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966-968
28. Fader M, Glickman S, Haggar V, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a Double-Blind, Randomized Crossover Trial. J Urol 2007;177:208-213
29. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27:214-218
30. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. J Urol 2006;25:441-445
31. Amend B, Hennenlotter J, Schafer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021
32. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-810
33. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-363
34. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-429
35. Pelman RS, Capo JP Jr, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med 2008;120:85-91
36. Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13:88-94
37. Anonymous. Managing incontinence due to detrusor instability. Drugs Ther Bull 2001;39:59-64
38. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-2358
39. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double blind, placebo-controlled clinical study. Eur Urol 2000;37:702-708
40. Mori S, Kojima M, Sakai Y, Nakajima K. Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nippon Ronen Igakkai Zasshi 1999;36:489-494
41. Stohrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 1999;37:196-200
42. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother 1999;33:1073-1082
43. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429
44. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Syst Rev 2007;4:CD003190
45. Wood S, Coulson R. Adverse drug reactions on-line information tracking (ADROIT). Pharm Med 1993;7:203-213
46. Alhasso AA, McKinley J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003193
47. McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25:337-348
48. Wallace S, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004;1:CD001308
49. De Ridder D, Vermeulen C, Ketelaer P, et al. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurologica Belgica 1999;99:61-64
50. Hay-Smith EJ, Bo K, Berghmans LC, et al. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2001;1:CD001407
51. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53:1270-1275
52. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:778-780
53. Dasgupta P, Haslam C, Goodwin R, Fowler CJ. The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. Br J Urol 1997;80:234-237
54. De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol 1997;158:2087-2092
55. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-457
56. Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry 1992;55:986-989
57. The National Collaborating Centre for Chronic Conditions at the Royal College of Physicians. Multiple sclerosis: National clinical guideline for diagnosis and management in primary and secondary care. The Royal College of Physicians. The Royal College of Physicians, London; 2004
58. Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2000;2:CD002113
59. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001;185:56-61
60. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol, Neurosurg Psychiatry 2009:80;470-477
61. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(Suppl 6A):36-52
62. Rabey JM, Moriel EZ, Farkas A, et al. Detrusor hyperreflexia in multiple sclerosis. Alleviation by a combination of imipramine and propantheline, a clinico-laboratory study. Eur Neurol 1979;18:33-37
63. Jensen D. Treatment of detrusor hyperreflexia in sclerosis multiplex. J Oslo City Hospital 1989;39:67-73
64. Bennett N, O'Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171:749-751